ClinicalTrials.gg
RecruitingNCT07606742VAMOS-MSUpdated Sep 17, 2026

Delivery of a Culturally Tailored Exercise Training Intervention for Hispanics With Multiple Sclerosis

An interventional study of Exercise Training in Multiple Sclerosis, sponsored by The University of Texas Health Science Center, Houston. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 10 studies in Multiple Sclerosis by The University of Texas Health Science Center, Houston — 3 open to participants now, 3 under way, none of them phase 3. Multiple Sclerosis · The University of Texas Health Science Center, Houston.

Started
2026
the only one that year
No phase
6 of 10
2 open now
Registered
9th of 10
by date

Among the 10 studies in Multiple Sclerosis by The University of Texas Health Science Center, Houston, this one is the only one that started in 2026, is one of 6 with no phase, and was the 9th registered.

Multiple Sclerosis

3,264 studies on the registry are indexed under Multiple Sclerosis; 659 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 10 studies in Multiple Sclerosis by The University of Texas Health Science Center, Houston are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 430 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 211 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Multiple Sclerosis by The University of Texas Health Science Center, Houston, or all of them as a file.
02

Study summary

The purpose of this study is to establish differences in the primary outcome of walking dysfunction using the 12-Item Multiple Sclerosis Walking Scale (MSWS-12) and to establish differences in the secondary outcome of HRQoL using the 29-Item Multiple Sclerosis Walking Scale (MSWS-29) between the exercise training intervention condition and the waitlist control condition following the 16-week intervention period.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Exercise training
  • mobility disability
  • implementation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of MS
  • relapse-free in the past 30 days
  • self-identify as Hispanic/Latino
  • Patient Determined Disease Steps Scale (PDDS) score between 3.0 (gait disability) and 6.0 (bilateral support) indicates walking disability.
  • MSWS-12 score between 25 and 75, indicating walking disability
  • Willingness to complete the questionnaires and undergo randomization
  • English or Spanish as a primary language

Exclusion criteria

Exclusion Criteria:

  • significant exercise-related risk factors or , assessed individually using the Physical Activity Readiness Questionnaire (PAR-Q; requires clearance from physician).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Exercise Training

    Behavioral: Exercise Training

  • No intervention
    Waitlist Control

Interventions

  • BehavioralExercise Training

    Participants will then be mailed exercise materials in their preferred language, including the program manual, logbook, calendar, newsletters, Fitbit, and resistance bands, along with instructions for telephone or video conference calls. This is a 16-week, home-based program, supported remotely via Internet-based behavioral coaching, which integrates behavior change techniques based on Social Cognitive Theory (SCT)

06

What researchers measure

Primary outcomes

  1. Change in walking ability as assessed by the 12-Item Multiple Sclerosis Walking Scale (MSWS-12)

    This is a 12 item questionnaire and each is scored on a 5-point Likert scale from 1(not at all) to 5(extremely). Total raw scores ranging from 12-60 are converted into standardized scores from 0-100, with higher scores indicating greater perceived walking impairment related to multiple sclerosis.

    Time frame: Baseline, 16 weeks, 32 weeks

Secondary outcomes

  1. Change in HRQoL as assessed by the 29-Item Multiple Sclerosis Walking Scale (MSWS-29)

    This is a 29 item questionnaire and each is scored from 1( not at all) to 5(extremely) , with a Raw score range from 29 to 145. This is then converted into a standardized scale from 0 to 100, with higher scores indicating worse walking impairment and greater impact of multiple sclerosis on mobility.

    Time frame: Baseline, 16 weeks, 32 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jun 2028, 22 months after the start.

Of 847 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 43. This study's planned 22 months is close to that.

Counting every sponsor, half of 869 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
May 26, 2026
StartActual
Aug 24, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Oct 31, 2028
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07606742
Responsible party
Stephanie Lee Silveira (Assistant Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
May 26, 2026
Start date
Aug 24, 2026
Primary completion
Jun 30, 2028 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Sep 17, 2026

Study contacts

Stephanie L Silveira, PhD
Contact
Stephanie.L.Silveira@uth.tmc.edu
(713) 500-9490
Najha Black
Contact
Najha.C.Marshall@uth.tmc.edu
713-500-9154
Stephanie L Silveira, PhD
principal investigator · The University of Texas Health Science Center, Houston

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion